CD274 and cancer: Recent evidence suggests that many other markers and mechanisms are involved in the dysregulation of the cancer-related immune system and this could explain non only the limited quota of effective responses to immunotherapy [12] but also the differences in expression of related markers such as PD-L1 [51].